Impact of cannabidiol on reward- and stress-related neurocognitive processes among individuals with opioid use disorder: A pilot, double-blind, placebo-controlled, randomized cross-over trial.
buprenorphine
cannabidiol
cue-induced craving
methadone
opioid use disorder
Journal
Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006
Informations de publication
Date de publication:
2023
2023
Historique:
received:
01
02
2023
accepted:
10
03
2023
medline:
18
4
2023
entrez:
17
4
2023
pubmed:
18
4
2023
Statut:
epublish
Résumé
Opioid use disorder (OUD) continues to be a significant public health concern. Medications for OUD (MOUD) such as buprenorphine reduce overdose mortality, but relapses occur often, leading to adverse outcomes. Preliminary data suggest that cannabidiol (CBD) may be a potential adjunctive treatment to MOUD by attenuating cue-reactivity. This pilot study sought to evaluate the impact of a single dose of CBD on reward- and stress-related neurocognitive processes implicated in relapse among those with OUD. The study was a pilot, double-blind, placebo-controlled, randomized cross-over trial aimed at assessing the effects of a single dose of CBD (Epidiolex®) 600 mg or matching placebo administered to participants with OUD receiving either buprenorphine or methadone. Vital signs, mood states, pain, opioid withdrawal, cue-induced craving, attentional bias, decision-making, delayed discount, distress tolerance, and stress-reactivity were examined at each testing session on two separate testing days at least 1 week apart. Ten participants completed all study procedures. Receipt of CBD was associated with a significant decrease in cue-induced craving (0.2 vs. 1.3, CBD may have promise as an adjunct to MOUD treatment by attenuating the brain response to drug-related cues, which, in turn, may reduce the risk of relapse and overdoses. Further research is warranted to evaluate the potential for CBD as an adjunctive therapy for individuals in treatment for OUD. https://clinicaltrials.gov/ct2/show/NCT04982029.
Identifiants
pubmed: 37065899
doi: 10.3389/fpsyt.2023.1155984
pmc: PMC10098189
doi:
Banques de données
ClinicalTrials.gov
['NCT04982029']
Types de publication
Journal Article
Langues
eng
Pagination
1155984Informations de copyright
Copyright © 2023 Suzuki, Prostko, Szpak, Chai, Spagnolo, Tenenbaum, Ahmed and Weiss.
Déclaration de conflit d'intérêts
RW has consulted to Alkermes. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Neuropsychopharmacology. 2018 Mar;43(4):859-867
pubmed: 29105663
J Pers Soc Psychol. 1988 Jun;54(6):1063-70
pubmed: 3397865
Neurotoxicology. 2019 Sep;74:282-298
pubmed: 31412258
Physiol Rev. 2019 Oct 1;99(4):2115-2140
pubmed: 31507244
J Clin Med. 2019 Jul 19;8(7):
pubmed: 31330972
Drug Alcohol Depend. 2015 Oct 1;155:60-7
pubmed: 26342626
BMJ. 2017 Apr 26;357:j1550
pubmed: 28446428
Neuropsychopharmacology. 2010 Aug;35(9):1879-85
pubmed: 20428110
Am J Addict. 2016 Mar;25(2):105-9
pubmed: 26848719
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
Curr Opin Behav Sci. 2018 Aug;22:59-69
pubmed: 29503841
Neurotherapeutics. 2015 Oct;12(4):807-15
pubmed: 26269227
Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
PLoS One. 2017 Jul 31;12(7):e0181955
pubmed: 28759635
Neuropsychopharmacology. 2011 May;36(6):1219-26
pubmed: 21307846
Psychopharmacology (Berl). 2018 Sep;235(9):2713-2723
pubmed: 29980821
Integr Med Rep. 2022 Aug 1;1(1):157-163
pubmed: 36105269
J Clin Med. 2021 Dec 14;10(24):
pubmed: 34945148
J Exp Psychol Gen. 1999 Mar;128(1):78-87
pubmed: 10100392
J Psychoactive Drugs. 2003 Apr-Jun;35(2):253-9
pubmed: 12924748
Front Psychiatry. 2019 Feb 19;10:63
pubmed: 30837904
MMWR Morb Mortal Wkly Rep. 2021 Feb 12;70(6):202-207
pubmed: 33571180
Addiction. 2018 May 1;:
pubmed: 29714034
CNS Spectr. 2014 Jun;19(3):225-30
pubmed: 23663386
Am J Drug Alcohol Abuse. 2018;44(5):502-511
pubmed: 29634425
Br J Pharmacol. 2015 Oct;172(20):4790-805
pubmed: 26218440
Neurotherapeutics. 2015 Oct;12(4):825-36
pubmed: 26341731
Psychiatr Serv. 2014 Feb 1;65(2):146-57
pubmed: 24248468
Health Psychol. 2020 Sep;39(9):806-814
pubmed: 32833482
JAMA Netw Open. 2018 Dec 7;1(8):e186466
pubmed: 30646331
Am J Addict. 2014 Sep-Oct;23(5):453-8
pubmed: 24628912
J Atten Disord. 2019 Sep;23(11):1229-1239
pubmed: 27282378
Am J Psychiatry. 2017 Aug 1;174(8):738-747
pubmed: 27978771
Cognition. 1994 Apr-Jun;50(1-3):7-15
pubmed: 8039375
Ann Acad Med Singap. 1994 Mar;23(2):129-38
pubmed: 8080219
Drug Alcohol Depend. 2015 Feb 1;147:243-50
pubmed: 25510307
Drug Alcohol Depend. 2021 Aug 1;225:108764
pubmed: 34051547
Addiction. 2004 Apr;99(4):461-71
pubmed: 15049746
Am J Psychiatry. 2019 Nov 1;176(11):911-922
pubmed: 31109198
Br J Pharmacol. 2015 Feb;172(3):737-53
pubmed: 25257544
J Neurosci. 2009 Nov 25;29(47):14764-9
pubmed: 19940171
Psychopharmacology (Berl). 2015 Oct;232(20):3685-96
pubmed: 26257163
Cochrane Database Syst Rev. 2004;(3):CD002207
pubmed: 15266465
Front Psychiatry. 2019 Aug 30;10:592
pubmed: 31543832
Psychol Sci Public Interest. 2019 Oct;20(2):96-127
pubmed: 31591935
Drug Alcohol Depend. 2008 Sep 1;97(1-2):1-20
pubmed: 18479844
Drug Alcohol Depend. 2021 Aug 1;225:108755
pubmed: 34052686